Navigation Links
China Diagnostic Reagent Industry Report, 2012-2014
Date:3/26/2013

DUBLIN, Ireland, March 26, 2013 /PRNewswire/ --

Research and Markets announces the addition of "China Diagnostic Reagent Industry Report, 2012-2014" to its catalogue.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

China's diagnostic reagent industry has formed a certain market scale and basis, and is marching from the introduction stage to the growth stage. With the continuous growth in China's medical care investment and per capita health care spending, the China's diagnostic reagent market has a promising prospect.

In vitro diagnostic reagents account for more than 90.0% of the output of China's diagnostic reagent industry. In 2011, the market scale of in vitro diagnostic reagents reached about RMB 11.4 billion in China, the industry will maintain a growth rate of 15%-20% in the future, and the market scale will hit RMB 20.8 billion in 2015.

At present, there are only a few integrated in vitro diagnostic reagent enterprises with strong strength in China's diagnostic reagent market, including KHB and Fosun Pharma; other enterprises such as Da An Gene, BioSino, Leadman and Livzon have competitive advantages in specific fields such as biochemical diagnosis, immunodiagnosis, and molecular diagnosis.

Meanwhile, China's in vitro diagnostic reagent industry concentration is low. Among 300-400 enterprises, there are only about 20 enterprises with annual sales of more than RMB 100 million. The enterprises are generally small and have a few product varieties. In 2011, KHB, Da An Gene, BioSino, Leadman only occupied 3.8%, 2.3%, 1.9%, 1.6% of the market respectively.

Key Topics Covered:

1. Overview of Diagnostic Reagent Industry

2. China Diagnostic Reagent Industry
2.1 Overview
2.2 Market Structure
2.3 Import and Export
2.3.1 Import
2.3.2 Export
2.4 Competitive Landscape
2.4.1 Biochemical Diagnostic Reagents
2.4.2 Immune Diagnostic Reagents
2.4.3 Molecular Diagnostic Reagents
2.4.4 Integrated In Vitro Diagnostic Reagents
2.5 Profitability
2.6 Entry Barriers
2.6.1 Technical Barriers
2.6.2 Quality and Brand Barriers
2.6.3 Marketing Channel Barriers
2.6.4 Market Access Barriers

3. Development Environment of China Diagnostic Reagent Industry
3.1 Policy Environment
3.1.1 Regulatory Policy
3.1.2 Industry Policy
3.2 Upstream and Downstream Industries
3.2.1 Industrial Chain
3.2.2 Upstream
3.2.3 Downstream

4. Development Forecast of China Diagnostic Reagent Industry
4.1 Overall Forecast
4.1.1 Market Demand Drivers
4.1.2 Market Scale Forecast
4.2 Development Trends of Diagnostic Reagent Industry
4.2.1 Biochemical Diagnosis and Immunodiagnosis Will Still Be the Mainstream
4.2.2 Industry Concentration Will Increase
4.2.3 Enterprises with Complete Product Line Integrating Reagents and Instruments will Win

5. Major Chinese Diagnostic Reagent Enterprises

Selected Charts

Companies Mentioned

- Acon Biotech (Hangzhou)
- Beijing Kinghawk Pharmaceutical
- Beijing Leadman Biochemistry
- Beijing North Institute of Biological Technology (BNIBT)
- Beijing Wantai Biological Pharmacy Enterprise
- BioSino Bio-technology and Science
- Blue Cross Bio-Medical (Beijing)
- Da An Gene
- Inverness Medical (Shanghai)
- Livzon Pharmaceutical Group
- Shanghai Fosun Pharmaceutical (Group)
- Shanghai Kehua Bio-engineering
- Shanghai Rongsheng Biotech
- Shanghai Upper Bio-Tech Pharma
- Shenzhen PG Biotech

For more information please visit Research and Markets.

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contact Details

Research and Markets
Laura Wood , Senior Manager.
press(at)researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Sector: Diagnostics



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
2. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
5. 3SBio Inc. to Present at the UBS Greater China Conference 2012
6. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
7. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
8. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
9. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
10. China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR
11. China Biologic Has Announced the Resignation of CFO Y. Tristan Kuo and Named Mr. Ming Yang as Interim CFO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
Breaking Biology Technology:
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):